Emcure Pharmaceuticals Ltd. was incorporated in the year 1981. Its today's share price is 0. Its current market capitalisation stands at Rs 0 Cr. In the latest quarter, company has reported Gross Sales of Rs. 31536.64 Cr and Total Income of Rs.32655.71 Cr. The company's management includes Vidya Yeravdekar, Vijay Gokhale, Samonnoi Banerjee, Palamadai Jayakumar, Shreekant Bapat, Mukund Gurjar, Namita Thapar, B Renganathan, Hitesh Jain, Shailesh Ayyangar, Sunil Mehta, Satish Mehta, Berjis…

Emcure Pharmaceuticals on Thursday said it has filed draft papers with Sebi for initial public offer (IPO). Sources said the size of the offer could be in the range of Rs 4,500-5,000 crore.

The offer comprised a fresh issue of shares aggregating up to Rs 1,100 crores and an offer for sale aggregating up to 18,168,356 shares. Promoters and private equity investor Bain Capital among those who will offload their shares.

Company proposes to utilise net proceeds from the fresh issue…

Emcure Pharmaceuticals Limited is an unlisted public company incorporated on 16 April, 1981. It is classified as a public limited company and is located in Pune, Maharashtra. It's authorized share capital is INR 250.00 cr and the total paid-up capital is INR 180.85 cr.

Emcure Pharmaceuticals Limited's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2021. It's EBITDA has increased by 75.57 % over the previous year. At the same time, it's book…

PUBLIC ISSUE OF [●] EQUITY SHARES OF FACE VALUE ` 10 EACH (THE “EQUITY SHARES”) OF EMCURE PHARMACEUTICALS LIMITED (THE

“COMPANY” OR THE “ISSUER”) FOR CASH AT A PRICE OF ` [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ` [●] PER EQUITY SHARE)

AGGREGATING TO ` [●] MILLION CONSISTING OF A FRESH ISSUE OF [●] EQUITY SHARES AGGREGATING UP TO ` 3,000 MILLION (THE “FRESH

ISSUE”) AND AN OFFER FOR SALE OF UP TO 2,513,057 EQUITY SHARES BY THE SELLING SHAREHOLDERS (AS DEFINED IN THE…

Emcure Pharmaceuticals, one of the fastest-growing drug makers by sales in the domestic market, is planning to strengthen its product portfolio with new launches, line extensions of existing brands and focus on digital sales.

The privately held Pune-based company aims to bring first to market specialty or differentiated generic drugs through the company’s own R&D efforts and innovative molecules through in-licensing partnerships.

In an interview to Moneycontrol, Namita…

Pune-based Emcure Pharmaceuticals Ltd, (Emcure) has entered into a collaboration with Swiss pharma major Roche for local manufacturing and marketing of Roche innovative molecules in India, under its supervision and as per Roche's technology.

The products – exactly the same as the original Roche formulation – will be made at Emcure’s Hinjewadi facility. They will be sold as both Emcure and Roche products under different brand names, Mukund Ranade, Executive Director, Emcure said that…

Satish Mehta, MD & CEO, Emcure Pharma is currently having a moment under the sun. Emcure’s subsidiary, Gennova, is developing India’s first indigenously developed mRNA COVID-19 vaccine that is currently undergoing phase II and phase III trials. Mehta is confident about meeting the said target of 60 million doses by the end of 2021, despite the logistics challenges. The company is working towards backward integration of its operations to help de-risk the supply chain.

Read more…

Emcure Pharmaceuticals Ltd is seeing new growth opportunities in biologics and vaccines which it intends to introduce in various emerging markets. Being the first Indian company to have developed an indigenous mRNA platform, it is in the process of developing an mRNA COVID-19 vaccine via its subsidiary Gennova Biopharmaceuticals Ltd., for which it has received funding from the Government of India. Three other vaccines on its mRNA platform are in development stages, targeted at Zoster, Zika…

Pune-based Emcure Pharmaceuticals has come forth again to publicly list its shares on exchanges.

In 2014, the company had attempted to hit the stock exchanges, but reportedly did not pursue it after Bain Capital invested about ₹226 crore, by which it was able to meet its immediate liquidity needs.

Now the initial public offering (IPO) comprises a fresh issue of ₹1,100 crore and an offer for sale of up to 1.81 crore equity shares that include promoters — Satish Mehta selling up to…

Pune-based Emcure Pharmaceuticals Limited, the 12th largest pharmaceutical company in India, has filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) for its initial public offering (IPO). Market sources say the company is planning an IPO for about Rs 4,000 crore, though it hasn't finalised the date of launching the issue.

The IPO will include a fresh issue of equity shares aggregating up to Rs 1,100 crores and an offer for…

Emcure Pharma: The leading pharma company is expected to float an IPO of Rs. 4500-5000 crore IPO . The initial public offering (IPO) comprises fresh issuance of equity shares worth Rs. 1,100 crore and an offer of sale (OFS) of 18,168,356 shares by promoters and existing shareholders, according to the draft red herring prospectus (DRHP). The company produces a broad range of pharma products across therapeutic areas.

Read more at…

Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma and life sciences companies are lined up to tap the equity markets through IPOs over the next few months, according to investment bankers.

Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based…

Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma and life sciences companies are lined up to tap the equity markets through IPOs over the next few months, according to investment bankers.

Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based…

Pune-based Emcure Pharmaceuticals Ltd is making its second attempt to float an initial public offering (IPO), joining a bunch of healthcare companies to tap into the stock market buoyancy.

Emcure has filed a draft prospectus with the capital markets regulator Securities and Exchange Board of India for the IPO that includes both primary and secondary share sales.

While the drugmaker aims to raise Rs 1,100 crore by issuing fresh shares in the IPO, its promoters and investor Bain…

Founded in 1983, Emcure Pharmaceuticals manufactures and globally markets a wide variety of pharmaceutical products. It has filed its draft red herring prospectus (DRHP) with the Securities Exchange Board of India (SEBI) to raise funds through an IPO (initial public offering). The company is aiming to raise ₹4,000 crore through this IPO.

The Pune-based company is the 12th largest pharmaceutical company in India. As per the CRISIL report FY21, Emcure Pharmaceutical Limited is a leader…

EMCURE PHARMACEUTICALS LIMITED is a 40.7 Years old company, incorporated on 16 Apr 1981. It is classified as Public UnListed Indian Non-Government Company. Its authorized share capital is ₹2,50,00,00,000.00 ( ₹250.00 Cr ) and its paid up capital is ₹1,80,85,21,160.00 ( ₹180.85 Cr ). As per MCA the main line of business is Manufacture Of Chemicals And Chemical Products.

EMCURE PHARMACEUTICALS LIMITED's Annual General Meeting (AGM) was last held on 30 Jul 2021 and as per records from…

Bain Capital-backed Emcure Pharmaceuticals has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial share sale.

The initial public offering (IPO) comprises fresh issuance of equity shares worth Rs 1,100 crore and an offer of sale of 18,168,356 shares by promoters and existing shareholders, according to the draft red herring prospectus (DRHP).…

Emcure Pharmaceuticals Limited, one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas, has filed its Draft Red Hearing Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds via initial public offering (IPO).…

Emcure Pharmaceuticals Limited is a Non-govt company, incorporated on 16 Apr, 1981. It's a public unlisted company and is classified as'company limited by shares'.

Company's authorized capital stands at Rs 20000.0 lakhs and has 90.42606% paid-up capital which is Rs 18085.21 lakhs. Emcure Pharmaceuticals Limited last annual general meet (AGM) happened on 08 Aug, 2017. The company last updated its financials on 31 Mar, 2017 as per Ministry of Corporate Affairs (MCA).…

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules and hard-gel capsules) and injectables.

Emcure is planning to raise money through an initial public offering for some time now.
https://en.wikipedia.org/wiki/Emcure_Pharmaceuticals